Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.

PLoS One · 2017 · PMC5590935 · PMID 28886175

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results of the HR NMA are consistent with the results of the survival curve NMA; the PFS for patients receiving cabozantinib was predicted to be superior and the OS showed a trend towards improvement (OS) compared to axitinib, everolimus, nivolumab and best supportive care.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.